top of page


The exceptional growth of biotherapeutics to a $125 billion industry has brought the benefit of targeted therapy to patients. However, as more and more biotherapeutic "generics" are developed, the risk of unwanted immunogenicity grows. ANP has successfully collaborated with biopharmaceutical companies to create novel solutions for immunogenicity and create new possibilities for biotherapeutics breakthroughs. From our highly sensitive NIDS® Streptavidin & Neutravidin plates to our unrivaled NIDS® immunogenicity assays, ANP is providing the innovation for healthcare transformation.

Lab Work
bottom of page